Table 1 Baseline characteristics and pregnancy outcomes of the SARS-CoV-2 diagnosed group, suspected infection group and uninfected group
SARS-CoV-2 uninfected group (n = 424) | SARS-CoV-2 diagnosed group (n = 687) | SARS-CoV-2 suspected infection group (n = 219) | P value | |
|---|---|---|---|---|
Age | 32.9 (4.7) | 32.6 (4.4) | 32.9 (4.7) | 0.6 |
BMI | 22.1 (2.6) | 21.9 (2.7) | 22.2 (2.6) | 0.10 |
Infertility type | 0.5 | |||
Primary | 25% (106/418) | 28% (190/682) | 24% (52/213) | |
Secondary | 75% (312/418) | 72% (492/682) | 76% (161/213) | |
Special diseases | ||||
PCOS | 21% (89/424) | 19% (132/687) | 21% (45/219) | 0.8 |
Endometriosis | 7% (28/424) | 7% (50/687) | 4% (8/219) | 0.2 |
Adenomyosis | 22% (93/424) | 23% (160/687) | 19% (41/219) | 0.4 |
Moderate to severe intrauterine adhesions | 21% (91/424) | 17% (118/687) | 19% (42/219) | 0.2 |
Untreated hydrosalpinx | 7% (28/424) | 6% (44/687) | 7% (16/219) | 0.9 |
Obesity | 2% (10/424) | 4% (25/687) | 1% (2/219) | 0.083 |
Diabetes | 0% (2/424) | 1% (5/687) | 1% (2/219) | 0.7 |
More than two mixed diseases | 19% (80/424) | 16% (113/687) | 16% (34/219) | 0.5 |
Top-quality embryo transfer rate | 63% (267/424) | 65% (446/687) | 65% (142/219) | 0.8 |
Embryo transfer cycle | 0.3 | |||
Fresh cycle | 23% (96/424) | 25% (175/687) | 21% (46/219) | |
FET cycle | 77% (328/424) | 75% (512/687) | 79% (173/219) | |
Endometrial thickness on the day of embryo transfer | 11 (2) | 12 (2) | 12 (2) | 0.073 |
Pregnancy outcomes | ||||
Clinical pregnancy rate | 63% (267/424) | 68% (464/687) | 51% (111/219) | < 0.001 |
Biochemical pregnancy rate | 10% (41/424) | 10% (70/687) | 12% (26/219) | 0.7 |
Ectopic pregnancy rate | 1% (6/424) | 1% (4/687) | 0% (1/219) | 0.3 |
Early miscarriage rate | 13% (34/263) | 13% (58/459) | 10% (11/109) | 0.7 |
Ongoing pregnancy rate | 53% (220/417) | 58% (394/678) | 45% (96/215) | 0.002 |